Complexity in the vascular permeability factor/vascular endothelial growth factor (VPF/VEGF)-receptors signaling

Molecular and Cellular Biochemistry

Volumn 264, Issue 1-2, 2004, Pages 51-61

  Mukhopadhyay, Debabrata ^a,b   Zeng, Huiyan ^a,b   Bhattacharya, Resham ^a,b  

^a MAYO CLINIC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cell signaling; Receptor tyrosine kinases; VEGF; VPF

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 MORPHOLINO 8 PHENYLCHROMONE; B LYMPHOCYTE RECEPTOR; BRADYKININ; CALCIUM; DOPAMINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHYLENE GLYCOL 1,2 BIS(2 AMINOPHENYL) ETHER N,N,N',N' TETRAACETIC ACID; FIBROBLAST GROWTH FACTOR; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPILIN; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE C; PROTEIN KINASE C; PROTEIN P85; RECOMBINANT VASCULOTROPIN; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; WORTMANNIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CAPILLARY; CELL BASED GENE THERAPY; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CORONARY ARTERY DISEASE; GENE DELIVERY SYSTEM; GENE THERAPY; HEART MUSCLE ISCHEMIA; HUMAN; NONHUMAN; NONVIRAL GENE THERAPY; PERIPHERAL VASCULAR DISEASE; REVIEW; SIGNAL TRANSDUCTION; STABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VIRAL GENE THERAPY;

AMINO ACID SEQUENCE; ANIMALS; CELL PROLIFERATION; CYTOKINES; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 5544275438     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:MCBI.0000044374.85095.df     Document Type: Review

References (74)

1. Folkman J: Tumor angiogenesis: Therapeutic implications. New Engl J Med 285: 1182-1186, 1971
2. Folkman J, Watson K, Ingber D, Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339: 58-61, 1989
3. Folkman J, Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987
4. Folkman J: Fighting cancer by attacking its blood supply. Sci Am 275: 150-154, 1996
5. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM: Vascular pelmeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237: 97-132, 1999
6. Risau W: Mechanisms of angiogenesis. Nature 386: 671-674, 1997
7. Benezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R: Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. Blood 81: 3324-3331, 1993
8. Senger DR, Perruzzi CA, Feder J, Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46: 5629-5632, 1986
9. Vlodavsky I, Fuks Z, Ishai-Michaeli R, Bashkin P, Levi E, Korner G, Bar-Shavit R, Klagsbrun M: Extracellular matrix-resident basic fibroblast growth factor: Implication for the control of angiogenesis. J Cell Biochem 45: 167-176, 1991
10. Dvorak HF, Orenstein NS, Carvalho AC, Churchill WH, Dvorak AM, Galli SJ, Feder J, Bitzer AM, Rypysc J, Giovinco P: Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 122: 166-174, 1979
11. Dvorak HF, Harvey VS, McDonagh J: Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res 44: 3348-3354, 1984
12. Dvorak HF: Leaky tumor vessels: Consequences for tumor stroma generation and for solid tumor therapy. Prog Clin Biol Res 354A: 317-330, 1990
13. Ferrara N: Vascular endothelial growth factor: Molecular and biological aspects. Curr Top Microbiol Immunol 237: 1-30, 1999
14. Seghezzi G, Patel S, Ren CJ, Gualandris A, Pintucci G, Robbins ES, Shapiro RL, Galloway AC, Rifkin DB, Mignatti P: Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis. J Cell Biol 141: 1659-1673, 1998
15. Leung DW, Cachianes G, Kuang W-J, Goeddel DV, Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989
16. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219: 983-985, 1983
17. Breier G: Functions of the VEGF/VEGF receptor system in the vascular system. Semin Thromb Hemost 26: 553-559, 2000
18. Chintalgattu V, Nair DM, Katwa LC: Cardiac myofibroblasts: A novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J Mol Cell Cardiol 35: 277-286, 2003
19. Rafii S, Meeus S, Dias S, Hattori K, Heissig B, Shmelkov S, Rafii D, Lyden D: Contribution of marrow-derived progenitors to vascular and cardiac regeneration. Semin Cell Dev Biol 13: 61-67, 2002
20. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B, Hicklin DJ, Zhu Z, Bohlen P, Witte L, Hendrikx J, Hackett NR, Crystal RG, Moore MA, Werb Z, Lyden D, Rafii S: Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bone-marrow microenvironment. Nat Med 8: 841-849, 2002
21. Eriksson U, Alitalo K: VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies. Nat Med 8: 775-777, 2002
22. Morishita R: Recent progress in gene therapy for cardiovascular disease. Circ J 66: 1077-1086, 2002
23. Heeschen C, Dimmeler S, Hamm CW, Boersma E, Zeiher AM, Simoons ML: Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation 107: 524-530, 2003
24. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER: The VIVA trial: Vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 107: 1359-1365, 2003
25. Lee CH, Smits PC: Vascular growth factors for coronary angiogenesis. J Interv Cardiol 15: 511-518, 2002
26. Vale PR, Isner JM, Rosenfield K: Therapeutic angiogenesis in critical limb and myocardial ischemia. J Interv Cardiol 14: 511-528, 2001
27. Khan TA, Sellke FW, Laham RJ: Gene therapy progress and prospects: Therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther 10: 285-291, 2003
28. Merkle CJ, Montgomery DW: Gene therapy with vascular endothelial growth factor reduces angina. J Cardiovasc Nurs 18: 38-43, 2003
29. Fong GH, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995
30. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Meller NPH, Risau W, Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993
31. Quinn TP, Peters KG, De Vries C, Ferrara N, Williams LT: Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium. Proc Natl Acad Sci USA 90: 7533-7537, 1993
32. Shalaby F, Ho J, Stanford WL, Fischer KD, Schuh AC, Schwartz L, Bernstein A, Rossant J: A requirement for Flk1 in primitive and definitive hematopoiesis and vasculogenesis. Cell 89: 981-990, 1997
33. Terman B, Dougher-Vermazen M, Carrion M, Dimitrov D, Almellino D, Gospodarowicz D, Bohlen P: Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 187: 1579-1586, 1992
34. Gagnon ML, Bielenberg DR, Gechtman Z, Miao HQ, Takashima S, Soker S, Klagsbrun M: Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc Natl Acad Sci USA 97: 2573-2578, 2000
35. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92: 735-745, 1998
36. Klagsbrun M, Takashima S, Mamluk R: The role of neuropilin in vascular and tumor biology. Adv Exp Med Biol 515: 33-48, 2002
37. Joukov V, Sorsa T, Kumar V, Jeltsch M, Claesson-Welsh L, Cao Y, Saksela O, Kalkkinen N, Alitalo K: Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J 16: 3898-3911, 1997
38. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH: Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269: 26988-26995, 1994
39. Petrova TV, Makinen T, Alitalo K: Signaling via vascular endothelial growth factor receptors. Exp Cell Res 253: 117-130, 1999
40. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, Schuh AC: Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995
41. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992
42. Kearney JB, Ambler CA, Monaco KA, Johnson N, Rapoport RG, Bautch VL: Vascular endothelial growth factor receptor Flt-1 negatively regulates developmental blood vessel formation by modulating endothelial cell division. Blood 99: 2397-2407, 2002
43. English J, Pearson G, Wilsbacher J, Swantek J, Karandikar M, Xu S, Cobb MH: New insights into the control of MAP kinase pathways. Exp Cell Res 253: 255-270, 1999
44. 2+ and von Willebrand factor release in human endothelial cells. Am J Pathol 138: 213-221, 1991
45. Zeng H, Dvorak HF, Mukhopadhyay D: Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2-mediated endothelial cell proliferation, but not migration, through phosphatidylinositol 3-kinase-dependent pathways. J Biol Chem 276: 26969-26979, 2001
46. Zeng H, Sanyal S, Mukhopadhyay D: Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 276: 32714-32719, 2001
47. Wu LW, Mayo LD, Dunbar JD, Kessler KM, Ozes ON, Warren RS, Donner DB: VRAP is an adaptor protein that binds KDR, a receptor for vascular endothelial cell growth factor. J Biol Chem 275: 6059-6062, 2000
48. Guo D, Jia Q, Song HY, Warren RS, Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729-6733, 1995
49. Rhee SG, Bae YS: Regulation of phosphoinositide-specific phospholipase C isozymes. J Biol Chem 272: 15045-15048, 1997
50. Mukai H, Munekata E, Higashijima T: G protein antagonists. A novel hydrophobic peptide competes with receptor for G protein binding. J Biol Chem 267: 16237-16243, 1992
51. Hunt RA, Bhat GJ, Baker KM: Angiotensin II-stimulated induction of sis-inducing factor is mediated by pertussis toxin-insensitive G(q) proteins in cardiac myocytes. Hypertension 34: 603-608, 1999
52. Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF: In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285: 1569-1572, 1999
53. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D: The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 61: 1768-1775, 2001
54. Gennity J, Siess W: Thrombin inhibits the pertussis-toxin-dependent ADP-ribosylation of a novel soluble Gi-protein in human platelets. Biochem J 279: 643-650, 1991
55. Takata M, Kurosaki T: A role for Bruton's tyrosine kinase in B cell antigen receptor-mediated activation of phospholipase C-gamma 2. J Exp Med 184: 31-40, 1996
56. Takahashi T, Ueno H, Shibuya M: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18: 2221-2230, 1999
57. Akhter SA, Luttrell LM, Rockman HA, Iaccarino G, Lefkowitz RJ, Koch WJ: Targeting the receptor-Gq interface to inhibit in vivo pressure overload myocardial hypertrophy. Science 280: 574-577, 1998
58. Koch WJ, Hawes BE, Inglese J, Luttrel LM, Lefkowitz RJ: Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling. J Biol Chem 269: 6193-6197, 1994
59. Kanno S, Oda N, Abe M, Terai Y, Ito M, Shitara K, Tabayashi K, Shibuya M, Sato Y: Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. Oncogene 19: 2138-2146, 2000
60. Bernatchez PN, Soker S, Sirois MG: Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent. J Biol Chem 274: 31047-31054, 1999
61. Gille H, Kowalski J, Yu L, Chen H, Pisabarro MT, Davis-Smyth T, Ferrara N: A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3′-kinase activation and endothelial cell migration. EMBO J 19: 4064-4073, 2000
62. Gille H, Kowalski J, Li B, LeCouter J, Moffat B, Zioncheck TF, Pelletier N, Ferrara N: Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem 276: 3222-3230, 2001
63. Cunningham SA, Waxham MN, Arrate PM, Brock TA: Interaction of the Flt-1 tyrosine kinase receptor with the p85 subunit of phosphatidylinositol 3-kinase. Mapping of a novel site involved in binding. J Biol Chem 270: 20254-20257, 1995
64. Bi L, Okabe I, Bernard DJ, Wynshaw-Boris A, Nussbaum RL: Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110 alpha submit of phosphoinositide 3-kinase. J Biol Chem 274: 10963-10968, 1999
65. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 95: 9349-9354, 1998
66. Zeng H, Zhao D, Mukhopadhyay D: Flt-1-mediated down-regulation of endothelial cell proliferation through pertussis toxin-sensitive G proteins, beta gamma subunits, small GTPase CDC42, and partly by Rac-1. J Biol Chem 277: 4003-4009, 2002
67. Voisin L, Foisy S, Giasson E, Lambert C, Moreau P, Meloche S: EGF receptor transactivation is obligatory for protein synthesis stimulation by G protein-coupled receptors. Am J Physiol Cell Physiol 283: C446-C455, 2002
68. Miura S, Matsuo Y, Saku K: Transactivation of KDR/Flk-1 by the B2 receptor induces tube formation in human coronary endothelial cells. Hypertension 41: 1118-1123, 2003
69. Zeng H, Zhao D, Yang S, Datta K, Mukhopadhyay D: Heterotrimeric G alpha q/G alpha 11 proteins function upstream of vascular endothelial growth factor (VEGF) receptor-2 (KDR) phosphorylation in vascular permeability factor/VEGF signaling. J Biol Chem 278: 20738-20745, 2003
70. Barleon B, Sozzani S, Zhou D, Weich HA, Mantovani A, Marme D: Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87: 3336-3343, 1996
71. Daub H, Wallasch C, Lankenau A, Herrlich A, Ullrich A: Signal characteristics of G protein-transactivated EGF receptor. EMBO J 16: 7032-7044, 1997
72. Tanimoto T, Jin ZG, Berk BC: Transactivation of vascular endothelial growth factor (VEGF) receptor Flk-1/KDR is involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt and endothelial nitric-oxide synthase (eNOS). J Biol Chem 277: 42997-43001, 2002
73. Thuringer D, Maulon L, Frelin C: Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277: 2028-2032, 2002
74. Kotecha SA, Oak JN, Jackson MF, Perez Y, Orser BA, Van Tol HH, MacDonald JF: A D2 class dopamine receptor transactivates a receptor tyrosine kinase to inhibit NMDA receptor transmission. Neuron 35: 1111-1122, 2002